Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy

B. Pieske, E. Pieske-Kraigher, CSP. Lam, V. Melenovský, K. Sliwa, Y. Lopatin, JL. Arango, MC. Bahit, CM. O'Connor, MJ. Patel, L. Roessig, DA. Morris, M. Kropf, CM. Westerhout, Y. Zheng, PW. Armstrong, VICTORIA Study Group

. 2023 ; 25 (7) : 1012-1021. [pub] 20230418

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23017019
E-zdroje Online Plný text

NLK Medline Complete (EBSCOhost) od 2000-03-01 do Před 1 rokem
Wiley Free Content od 1999 do Před 1 rokem

Odkazy

PubMed 36994634
DOI 10.1002/ejhf.2836
Knihovny.cz E-zdroje

AIM: Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF. METHODS AND RESULTS: Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co-primary endpoints were changes in LV end-systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high-quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 ± 26.8 to 56.8 ± 30.4 ml/m2 ; p < 0.01) and LVEF significantly increased (33.0 ± 9.4% to 36.1 ± 10.2%; p < 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI -3.8 ± 15.4 vs. -7.1 ± 20.5 ml/m2 ; p = 0.07 and LVEF +3.2 ± 8.0% vs. +2.4 ± 7.6%; p = 0.31). The absolute rate per 100 patient-years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p = 0.07). CONCLUSIONS: In this pre-specified echocardiographic study, significant improvements in LV structure and function occurred over 8 months in both vericiguat and placebo in a high-risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat's benefit in HFrEF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23017019
003      
CZ-PrNML
005      
20231026105333.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ejhf.2836 $2 doi
035    __
$a (PubMed)36994634
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pieske, Burkert $u Charité University Medicine, German Heart Center, Berlin, Germany
245    10
$a Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy / $c B. Pieske, E. Pieske-Kraigher, CSP. Lam, V. Melenovský, K. Sliwa, Y. Lopatin, JL. Arango, MC. Bahit, CM. O'Connor, MJ. Patel, L. Roessig, DA. Morris, M. Kropf, CM. Westerhout, Y. Zheng, PW. Armstrong, VICTORIA Study Group
520    9_
$a AIM: Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF. METHODS AND RESULTS: Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co-primary endpoints were changes in LV end-systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high-quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 ± 26.8 to 56.8 ± 30.4 ml/m2 ; p < 0.01) and LVEF significantly increased (33.0 ± 9.4% to 36.1 ± 10.2%; p < 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI -3.8 ± 15.4 vs. -7.1 ± 20.5 ml/m2 ; p = 0.07 and LVEF +3.2 ± 8.0% vs. +2.4 ± 7.6%; p = 0.31). The absolute rate per 100 patient-years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p = 0.07). CONCLUSIONS: In this pre-specified echocardiographic study, significant improvements in LV structure and function occurred over 8 months in both vericiguat and placebo in a high-risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat's benefit in HFrEF.
650    _2
$a lidé $7 D006801
650    12
$a srdeční selhání $x diagnostické zobrazování $x farmakoterapie $x chemicky indukované $7 D006333
650    _2
$a tepový objem $7 D013318
650    12
$a heterocyklické sloučeniny bicyklické $7 D006574
650    _2
$a funkce levé komory srdeční $7 D016277
650    _2
$a echokardiografie $7 D004452
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pieske-Kraigher, Elisabeth $u Charité University Medicine, German Heart Center, Berlin, Germany
700    1_
$a Lam, Carolyn S P $u National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Sliwa, Karen $u Cape Heart Institute, University of Cape Town, Cape Town, South Africa
700    1_
$a Lopatin, Yuri $u Volgograd State Medical University, Volgograd Regional Cardiology Center, Volgograd, Russian Federation
700    1_
$a Arango, Juan Luis $u Unidad de Cirugía Cardiovascular de Guatemala, Guatemala City, Guatemala
700    1_
$a Bahit, M Cecilia $u INECO Neurociencias Oroño, Fundación INECO, Rosario, Argentina
700    1_
$a O'Connor, Christopher M $u Inova Heart and Vascular Institute, Falls Church, VA, USA
700    1_
$a Patel, Mahesh J $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Roessig, Lothar $u Bayer AG, Wuppertal, Germany
700    1_
$a Morris, Daniel A $u Charité University Medicine, German Heart Center, Berlin, Germany
700    1_
$a Kropf, Martin $u Charité University Medicine, German Heart Center, Berlin, Germany
700    1_
$a Westerhout, Cynthia M $u Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada
700    1_
$a Zheng, Yinggan $u Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada
700    1_
$a Armstrong, Paul W $u Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada
710    2_
$a VICTORIA Study Group
773    0_
$w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 25, č. 7 (2023), s. 1012-1021
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36994634 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105328 $b ABA008
999    __
$a ok $b bmc $g 2000505 $s 1203381
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 7 $d 1012-1021 $e 20230418 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace